| Janelle Marie Fauci, MD | |
|
125 Queens Rd Ste 540, Charlotte, NC 28204-3215 | |
| (980) 302-6560 | |
| (980) 302-6565 |
| Full Name | Janelle Marie Fauci |
|---|---|
| Gender | Female |
| Speciality | Gynecological Oncology |
| Experience | 17 Years |
| Location | 125 Queens Rd Ste 540, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144423542 | NPI | - | NPPES |
| 051116596 | Other | AL | BCBS |
| 128474 | Medicaid | AL | |
| 128468 | Medicaid | AL | |
| 051116590 | Other | AL | BCBS |
| 051116591 | Other | AL | BCBS |
| 051116592 | Other | AL | BCBS |
| 128470 | Medicaid | AL | |
| 051116594 | Other | AL | BCBS |
| 1144423542 | Medicaid | NC | |
| 128475 | Medicaid | AL | |
| 051116593 | Other | AL | BCBS |
| 128471 | Medicaid | AL | |
| 128473 | Medicaid | AL | |
| 01905778 | Medicaid | MS | |
| 051116595 | Other | AL | BCBS |
| 128472 | Medicaid | AL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Presbyterian Medical Center | Charlotte, NC | Hospital |
| Novant Health Matthews Medical Center | Matthews, NC | Hospital |
| Novant Health Mint Hill Medical Center | Charlotte, NC | Hospital |
| Novant Health Huntersville Medical Center | Huntersville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Presbyterian Hospital | 1153231907 | 359 |
News Archive
A new partnership announced by the Canadian Diabetes Association and the University of British Columbia (UBC) will help fund research in childhood diabetes. Not only will this research further investigate type 1 diabetes, it will also explore the areas of type 2 diabetes and obesity in children, a problem of growing concern and proportions.
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
› Verified 3 days ago
| Entity Name | The Presbyterian Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053365817 PECOS PAC ID: 1153231907 Enrollment ID: O20040223001121 |
News Archive
A new partnership announced by the Canadian Diabetes Association and the University of British Columbia (UBC) will help fund research in childhood diabetes. Not only will this research further investigate type 1 diabetes, it will also explore the areas of type 2 diabetes and obesity in children, a problem of growing concern and proportions.
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janelle Marie Fauci, MD Po Box 60447, Charlotte, NC 28260-0447 Ph: () - | Janelle Marie Fauci, MD 125 Queens Rd Ste 540, Charlotte, NC 28204-3215 Ph: (980) 302-6560 |
News Archive
A new partnership announced by the Canadian Diabetes Association and the University of British Columbia (UBC) will help fund research in childhood diabetes. Not only will this research further investigate type 1 diabetes, it will also explore the areas of type 2 diabetes and obesity in children, a problem of growing concern and proportions.
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology.
Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
› Verified 3 days ago
Jackie Alan Lucas, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 450, Charlotte, NC 28204 Phone: 704-446-7800 | |
Lynn Amy Boardman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Dr. Simon Vivian Ward Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1918 Randolph Rd, Suite 670, Charlotte, NC 28207 Phone: 704-384-1620 Fax: 704-384-1626 | |
Curtis Lee Flood, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6331 Carmel Rd Ste 102, Charlotte, NC 28226 Phone: 980-367-4363 Fax: 704-316-2558 | |
Grant Blanchard, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 | |
Roland Pixley, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1025 Morehead Medical Dr, Ste 400, Charlotte, NC 28204 Phone: 704-446-1700 | |
Katherine Elizabeth Akeley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1544 |